The Journal of Practical Medicine >

2026 , Vol. 42 >Issue 4: 541 - 550

DOI: https://doi.org/10.3969/j.issn.1006-5725.2026.04.001

Guidelines Interpretation

Interpretation of key updates of global strategy for the diagnosis， management， and prevention of Chronic Obstructive Pulmonary Disease 2026 Report

  • Shengming LIU
Expand
  • Department of Pulmonary and Critical Care Medicine，the First Affiliated Hospital of Jinan University，Guangzhou 510630，Guangdong，China

Received date: 2025-12-08

  Online published: 2026-02-25

Fold

Abstract

The GOLD 2026 report presents several significant updates in the diagnosis， treatment， management， and prevention of chronic obstructive pulmonary disease （COPD）. For the very first time， this report integrates the concept of “disease activity”， spotlighting low disease activity as a core treatment objective. In terms of exacerbation risk stratification， patients who have experienced one or more moderate-to-severe exacerbations in the past year are categorized as high-risk， underscoring the significance of early detection and intervention. Vaccination strategies have been revised as well： the lower age threshold for respiratory syncytial virus （RSV） vaccination has been lowered to 50 years， an mRNA vaccine option has been introduced， and the evidence backing influenza vaccination in high-risk populations has been reinforced. The section on biologics demonstrates their effectiveness through evidence-based charts， which support precision-targeted therapy. The chapter on comorbidity management introduces the multimorbidity （syndemics concept） and utilizes the 4Ms framework to comprehensively tackle cardiovascular， respiratory， psychiatric， and metabolic comorbidities， along with clear instructions on corresponding interventions. Moreover， the report officially incorporates artificial intelligence and telemedicine into the clinical workflow. Overall， these updates signify a transition in COPD management towards a more proactive， precise， and comprehensive approach， offering crucial guidance for individualized treatment and optimized long-term care. This article intends to systematically summarize the key updates in GOLD 2026 to inform clinical practice.

Key words： chronic obstructive pulmonary disease; disease activity; acute exacerbation; biologics; vaccination; comorbidity management

Cite this article

Shengming LIU . Interpretation of key updates of global strategy for the diagnosis， management， and prevention of Chronic Obstructive Pulmonary Disease 2026 Report[J]. The Journal of Practical Medicine, 2026 , 42(4) : 541 -550 . DOI: 10.3969/j.issn.1006-5725.2026.04.001

References

[1] Global Initiative for Chronic Ob structive Lung Disease. Global strategy for prevention， diagnosis and management of COPD： 2026 Report ［/OL］. （2025-11-17）［2025-12-08］. .
[2] WANG Z， LIN J， LIANG L， et al. Global， regional， and national burden of chronic obstructive pulmonary disease and its attributable risk factors from 1990 to 2021： An analysis for the Global Burden of Disease Study 2021［J］. Respir Res， 2025， 26（1）： 2. doi：10.1186/s12931-024-03051-2 .
[3] ADELOYE D， SONG P， ZHU Y， et al. Global， regional， and national prevalence of， and risk factors for， chronic obstructive pulmonary disease （COPD） in 2019： A systematic review and modelling analysis［J］. Lancet Respir Med， 2022， 10（5）： 447-458. doi：10.1016/S2213-2600（21）00511-7 .
[4] LAMPRECHT B， SORIANO J B， STUDNICKA M， et al. Determinants of underdiagnosis of COPD in national and international surveys［J］. Chest， 2015， 148（4）： 971-985. doi：10.1378/chest.14-2535 .
[5] BOERS E， ALLEN A， BARRETT M， et al. Forecasting the global economic and health burden of COPD from 2025 through 2050［J］. Chest， 2025， 168（4）： 880-889. doi：10.1016/j.chest. 2025.03.029 .
[6] STOLBRINK M， THOMSON H， HADFIELD R M， et al. The availability， cost， and affordability of essential medicines for asthma and COPD in low-income and middle-income countries： A systematic review［J］. Lancet Glob Health， 2022， 10（10）： e1423-e1442. doi：10.1016/S2214-109X（22）00330-8 .
[7] DE OCA M M， PEREZ-PADILLA R， CELLI B， et al. The global burden of COPD： Epidemiology and effect of prevention strategies［J］. Lancet Respir Med， 2025， 13（8）： 709-724. doi：10.1016/S2213-2600（24）00339-4 .
[8] PERRET J L， VICENDESE D， SIMONS K， et al. Ten-year prediction model for post-bronchodilator airflow obstruction and early detection of COPD： Development and validation in two middle-aged population-based cohorts［J］. BMJ Open Respir Res， 2021， 8（1）： e001138. doi：10.1136/bmjresp-2021-001138 .
[9] AARON S D， MONTES DE OCA M， CELLI B， et al. Early diagnosis and treatment of chronic obstructive pulmonary disease： The costs and benefits of case finding［J］. Am J Respir Crit Care Med， 2024， 209（8）： 928-937. doi：10.1164/rccm.202311-2120PP .
[10] WEBBER E M， LIN J S， THOMAS R G. Screening for chronic obstructive pulmonary disease： Updated evidence report and systematic review for the US preventive services task force［J］. JAMA， 2022， 327（18）： 1812-1816. doi：10.1001/jama. 2022. 4708 .
[11] HALPIN D M. Do the ‘missing millions’ of COPD patients want to be found？［J］. Thorax， 2023， 78（6）： 531-532. doi：10.1136/thorax-2023-220113 .
[12] DIRVEN J A M， TANGE H J， MURIS J W M， et al. Early detection of COPD in general practice： Implementation， workload and socioeconomic status. A mixed methods observational study［J］. Prim Care Respir J， 2013， 22（3）： 338-343. doi：10.4104/pcrj. 2013.00071 .
[13] LE ROUZIC O， ROCHE N， CORTOT A B， et al. Defining the “frequent exacerbator” phenotype in COPD： A hypothesis-free approach［J］. Chest， 2018， 153（5）： 1106-1115. doi：10.1016/j.chest.2017.10.009 .
[14] HILL K， GOLDSTEIN R S， GUYATT G H， et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care［J］. CMAJ， 2010， 182（7）： 673-678. doi：10.1503/cmaj.091784 .
[15] WODI A P， ISSA A N， MOSER C A， et al. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older-United States， 2025［J］. MMWR Morb Mortal Wkly Rep， 2025， 74（2）： 30-33. doi：10.15585/mmwr.mm7402a3 .
[16] WILSON E， GOSWAMI J， BAQUI A H， et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults［J］. N Engl J Med， 2023， 389（24）： 2233-2244. doi：10.1056/NEJMoa2307079 .
[17] ISON M G， PAPI A， ATHAN E， et al. Efficacy and safety of respiratory syncytial virus （RSV） prefusion F protein vaccine （RSVPreF3 OA） in older adults over 2 RSV seasons［J］. Clin Infect Dis， 2024， 78（6）： 1732-1744. doi：10.1093/cid/ciae010 .
[18] ISON M G， PAPI A， ATHAN E， et al. Efficacy， safety， and immunogenicity of the AS01（E）-adjuvanted respiratory syncytial virus prefusion F protein vaccine （RSVPreF3 OA） in older adults over three respiratory syncytial virus seasons （AReSVi-006）： A multicentre， randomised， observer-blinded， placebo-controlled， phase 3 trial［J］. Lancet Respir Med， 2025， 13（6）： 517-529. doi：10.1016/S2213-2600（25）00048-7 .
[19] GROHSKOPF L A， BLANTON L H， FERDINANDS J M， et al. Prevention and control of seasonal influenza with vaccines： Recommendations of the advisory committee on immunization practices - United States， 2022-23 influenza season［J］. MMWR Recomm Rep， 2022， 71（1）： 1-28. doi：10.15585/mmwr.rr7101a1 .
[20] EDWARDS K M， DUPONT W D， WESTRICH M K， et al. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease［J］. J Infect Dis， 1994， 169（1）： 68-76. doi：10.1093/infdis/169.1.68 .
[21] ANDERSON C S， HUA C， WANG Z， et al. Influenza vaccination to improve outcomes for patients with acute heart failure （PANDA II）： A multiregional， seasonal， hospital-based， cluster-randomised， controlled trial in China［J］. Lancet， 2025， 406（10507）： 1020-1031. doi：10.1016/S0140-6736（25）01485-0 .
[22] LIPSON D A， BARNHART F， BREALEY N， et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD［J］. N Engl J Med， 2018， 378（18）： 1671-1680. doi：10.1056/NEJMoa1713901 .
[23] RABE K F， MARTINEZ F J， FERGUSON G T， et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD［J］. N Engl J Med， 2020， 383（1）： 35-48. doi：10.1056/NEJMoa1916046 .
[24] SINGH D， FABBRI L M， CORRADI M， et al. Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation［J］. Eur Respir J， 2019， 53（5）： 1900235. doi：10.1183/13993003.00235-2019 .
[25] HALPIN D M G， DRANSFIELD M T， HAN M K， et al. The effect of exacerbation history on outcomes in the IMPACT trial［J］. Eur Respir J， 2020， 55（5）： 1901921. doi：10.1183/13993003. 01921-2019 .
[26] SINGH D， HAN M K， BHATT S P， et al. Is disease stability an attainable chronic obstructive pulmonary disease treatment goal？［J］. Am J Respir Crit Care Med， 2025， 211（3）： 452-463. doi：10.1164/rccm.202406-1254CI .
[27] SOLER-CATALU?A J J， VILLAGRASA M， CATALáN P， et al. Risk validation of a new quantitative score for clinical control of chronic obstructive pulmonary disease： The RADAR score［J］. Arch De Bronconeumología， 2026， 62（1）： 28-34. doi：10.1016/j.arbres.2025.06.003 .
[28] KIM S H， LEE H， JOO H， et al. Risk of rapid lung function decline in young adults with chronic obstructive pulmonary disease： A community-based prospective cohort study［J］. J Korean Med Sci， 2023， 38（1）： e3. doi：10.3346/jkms.2023.38.e3 .
[29] WU M， WANG Z， LI M， et al. Daily symptom variability in patients with stable COPD： A narrative review［J］. West J Nurs Res， 2018， 40（10）： 1543-1561. doi：10.1177/0193945917705132 .
[30] SINGH D， AGUSTI A， MARTINEZ F J， et al. Blood eosinophils and chronic obstructive pulmonary disease： A global initiative for chronic obstructive lung disease science committee 2022 review［J］. Am J Respir Crit Care Med， 2022， 206（1）： 17-24. doi：10.1164/rccm.202201-0209PP .
[31] BHATT S P， RABE K F， HANANIA N A， et al. Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation［J］. N Engl J Med， 2024， 390（24）： 2274-2283. doi：10.1056/nejmoa2401304 .
[32] BHATT S P， RABE K F， HANANIA N A， et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts［J］. N Engl J Med， 2023， 389（3）： 205-214. doi：10.1056/NEJMoa2303951 .
[33] FIELDES M， BOURGUIGNON C， ASSOU S， et al. Targeted therapy in eosinophilic chronic obstructive pulmonary disease［J］. ERJ Open Res， 2021， 7（2）： 437-2020. doi：10.1183/23120541. 00437-2020 .
[34] PAVORD I D， CHANEZ P， CRINER G J， et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease［J］. N Engl J Med， 2017， 377（17）： 1613-1629. doi：10.1056/NEJMoa1708208 .
[35] SCIURBA F C， CRINER G J， CHRISTENSON S A， et al. Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype［J］. N Engl J Med， 2025， 392（17）： 1710-1720. doi：10.1056/NEJMoa2413181 .
[36] LI S， YI B， WANG H， et al. Efficacy and safety of biologics targeting type 2 inflammation in COPD： A systematic review and network meta-analysis［J］. Int J Chron Obstruct Pulmon Dis， 2025， 20： 2143-2159. doi：10.2147/COPD.S504774 .
[37] PITRE T， LUPAS D， MAH J， et al. Biologic therapies for chronic obstructive pulmonary disease： A systematic review and network meta-analysis of randomized controlled trials［J］. COPD， 2025， 22（1）： 2449889. doi：10.1080/15412555.2025.2449889 .
[38] HU K C， CHUANG M H， LAI C C， et al. Meta-analysis of randomized， controlled trials assessing the effectiveness and safety of biological treatments in chronic obstructive pulmonary disease patients［J］. Clin Ther， 2025， 47（3）： 226-234. doi：10.1016/j.clinthera.2024.12.001 .
[39] MAPPIN-KASIRER B， PAVORD I D. Biological therapies in chronic obstructive pulmonary disease： New directions in personalised respiratory medicine［J］. BioDrugs， 2025， 39（6）： 827-839. doi：10.1007/s40259-025-00744-y .
[40] PHILLIPS K M， LAVERE P F， HANANIA N A， et al. The emerging biomarkers in chronic obstructive pulmonary disease： A narrative review［J］. Diagnostics， 2025， 15（10）： 1245. doi：10.3390/diagnostics15101245 .
[41] XIE C， WANG K， YANG K， et al. Toward precision medicine in COPD： Phenotypes， endotypes， biomarkers， and treatable traits［J］. Respir Res， 2025， 26（1）： 274. doi：10.1186/s12931-025-03356-w .
[42] CELLI B R， FABBRI L M， AARON S D， et al. An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations： The Rome proposal［J］. Am J Respir Crit Care Med， 2021， 204（11）： 1251-1258. doi：10.1164/rccm. 202108-1819PP .
[43] CELLI B R， FABBRI L M， AARON S D， et al. Differential diagnosis of suspected chronic obstructive pulmonary disease exacerbations in the acute care setting： Best practice［J］. Am J Respir Crit Care Med， 2023， 207（9）： 1134-1144. doi：10.1164/rccm. 202209-1795CI .
[44] PAPI A， BELLETTATO C M， BRACCIONI F， et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations［J］. Am J Respir Crit Care Med， 2006， 173（10）： 1114-1121. doi：10.1164/rccm.200506-859OC .
[45] BAFADHEL M， MCKENNA S， TERRY S， et al. Acute exacerbations of chronic obstructive pulmonary disease： Identification of biologic clusters and their biomarkers［J］. Am J Respir Crit Care Med， 2011， 184（6）： 662-671. doi：10.1164/rccm.201104-0597OC .
[46] SETHI S， SETHI R， ESCHBERGER K， et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease［J］. Am J Respir Crit Care Med， 2007， 176（4）： 356-361. doi：10.1164/rccm.200703-417OC .
[47] CRISAFULLI E， MANCO A， FERRER M， et al. Pneumonic versus nonpneumonic exacerbations of chronic obstructive pulmonary disease［J］. Semin Respir Crit Care Med， 2020， 41（6）： 817-829. doi：10.1055/s-0040-1702196 .
[48] TORRES A， BLASI F， DARTOIS N， et al. Which individuals are at increased risk of pneumococcal disease and why？ Impact of COPD， asthma， smoking， diabetes， and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease［J］. Thorax， 2015， 70（10）： 984-989. doi：10.1136/thoraxjnl-2015-206780 .
[49] RESTREPO M I， MORTENSEN E M， PUGH J A， et al. COPD is associated with increased mortality in patients with community-acquired pneumonia［J］. Eur Respir J， 2006， 28（2）： 346-351. doi：10.1183/09031936.06.00131905 .
[50] BRAEKEN D C， ROHDE G G， FRANSSEN F M， et al. Risk of community-acquired pneumonia in chronic obstructive pulmonary disease stratified by smoking status： A population-based cohort study in the United Kingdom［J］. Int J Chron Obstruct Pulmon Dis， 2017， 12： 2425-2432. doi：10.2147/COPD.S138435 .
[51] RELLO J， RODRIGUEZ A， TORRES A， et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia［J］. Eur Respir J， 2006， 27（6）： 1210-1216. doi：10.1183/09031936.06.00139305 .
[52] BEGHé B， VERDURI A， ROCA M， et al. Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD［J］. Eur Respir J， 2013， 41（4）： 993-995. doi：10.1183/09031936.00180812 .
[53] STOLZ D， BREIDTHARDT T， CHRIST-CRAIN M， et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD［J］. Chest， 2008， 133（5）： 1088-1094. doi：10.1378/chest.07-1959 .
[54] GRAUL E L， NORDON C， RHODES K， et al. Temporal risk of nonfatal cardiovascular events after chronic obstructive pulmonary disease exacerbation： A population-based study［J］. Am J Respir Crit Care Med， 2024， 209（8）： 960-972. doi：10.1164/rccm.202307-1122OC .
[55] KUNISAKI K M， DRANSFIELD M T， ANDERSON J A， et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events： A post hoc cohort analysis from the SUMMIT randomized clinical trial［J］. Am J Respir Crit Care Med， 2018， 198（1）： 51-57. doi：10.1164/rccm.201711-2239OC .
[56] DONALDSON G C， HURST J R， SMITH C J， et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD［J］. Chest， 2010， 137（5）： 1091-1097. doi：10.1378/chest.09-2029 .
[57] COUTURAUD F， BERTOLETTI L， PASTRE J， et al. Prevalence of pulmonary embolism among patients with COPD hospitalized with acutely worsening respiratory symptoms［J］. JAMA， 2021， 325（1）： 59-68. doi：10.1001/jama.2020.23567 .
[58] JIMéNEZ D， AGUSTí A， TABERNERO E， et al. Effect of a pulmonary embolism diagnostic strategy on clinical outcomes in patients hospitalized for COPD exacerbation： A randomized clinical trial［J］. JAMA， 2021， 326（13）： 1277-1285. doi：10.1001/jama. 2021.14846 .
[59] WALLSTR?M O， STRIDSMAN C， LINDBERG A， et al. Exacerbation history and risk of myocardial infarction and pulmonary embolism in COPD［J］. Chest， 2024， 166（6）： 1347-1359. doi：10.1016/j.chest.2024.07.150 .
[60] LEUPPI J D， SCHUETZ P， BINGISSER R， et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease： The REDUCE randomized clinical trial［J］. JAMA， 2013， 309（21）： 2223-2231. doi：10.1001/jama.2013.5023 .
[61] WALTERS J A， TAN D J， WHITE C J， et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease［J］. Cochrane Database Syst Rev， 2018， 3（3）： CD006897. doi：10.1002/14651858.CD006897.pub4 .
[62] FABBRI L M， CELLI B R， AGUSTí A， et al. COPD and multimorbidity： Recognising and addressing a syndemic occurrence［J］. Lancet Respir Med， 2023， 11（11）： 1020-1034. doi：10.1016/S2213-2600（23）00261-8 .
[63] DIVO M， COTE C， DE TORRES J P， et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease［J］. Am J Respir Crit Care Med， 2012， 186（2）： 155-161. doi：10.1164/rccm.201201-0034OC .
[64] FABBRI L M， LUPPI F， BEGHé B， et al. Complex chronic comorbidities of COPD［J］. Eur Respir J， 2008， 31（1）： 204-212. doi：10.1183/09031936.00114307 .
[65] YOHANNES A M. Palliative care provision for patients with chronic obstructive pulmonary disease［J］. Health Qual Life Outcomes， 2007， 5： 17. doi：10.1186/1477-7525-5-17 .
[66] MANNING J M. The 4M model［J］. Crit Care Nurs Clin N Am， 2023， 35（4）： 367-374. doi：10.1016/j.cnc.2023.06.003 .
[67] MATE K， FULMER T， PELTON L， et al. Evidence for the 4Ms： Interactions and outcomes across the care continuum［J］. J Aging Health， 2021， 33（7-8）： 469-481. doi：10.1177/0898264321991658 .
[68] AARON S D， VANDEMHEEN K L， WHITMORE G A， et al. Early diagnosis and treatment of COPD and asthma - a randomized， controlled trial［J］. N Engl J Med， 2024， 390（22）： 2061-2073. doi：10.1056/NEJMoa2401389 .
[69] MEI S， LI X， ZHOU Y， et al. Deep learning for detecting and early predicting chronic obstructive pulmonary disease from spirogram time series［J］. NPJ Syst Biol Appl， 2025， 11（1）： 18. doi：10.1038/s41540-025-00489-y .
[70] CASTRO M， PAPI A， PORSBJERG C， et al. Effect of dupilumab on exhaled nitric oxide， mucus plugs， and functional respiratory imaging in patients with type 2 asthma （VESTIGE）： A randomised， double-blind， placebo-controlled， phase 4 trial［J］. Lancet Respir Med， 2025， 13（3）： 208-220. doi：10.1016/S2213-2600（24）00362-X .
[71] CARRASCO-ZANINI J， PIETZNER M， DAVITTE J， et al. Proteomic signatures improve risk prediction for common and rare diseases［J］. Nat Med， 2024， 30（9）： 2489-2498. doi：10.1038/s41591-024-03142-z .
[72] OLVERA N， SáNCHEZ-VALLE J， Nú?EZ-CARPINTERO I， et al. Lung tissue multilayer network analysis uncovers the molecular heterogeneity of chronic obstructive pulmonary disease［J］. Am J Respir Crit Care Med， 2024， 210（10）： 1219-1229. doi：10.1164/rccm.202303-0500OC .
[73] ZHU Y， WANG M， GU X N， et al. Development and validation of the machine learning model for acute exacerbation of chronic obstructive pulmonary disease prediction based on inflammatory biomarkers［J］. Front Med， 2025， 12： 1616712. doi：10.3389/fmed.2025.1616712 .
[74] CHEN Z， HAO J， SUN H， et al. Applications of digital health technologies and artificial intelligence algorithms in COPD： Systematic review［J］. BMC Med Inform Decis Mak， 2025， 25（1）： 77. doi：10.1186/s12911-025-02870-7 .
[75] CHAMAON D， SPORTEL E， ELFERINK E C M， et al. Validation of an AI-powered smart dry powder inhaler （RS01X） for asthma and COPD in a clinical setting［J］. Int J Chron Obstruct Pulmon Dis， 2025， 20： 811-819. doi：10.2147/COPD.S490684 .
Options
Outlines

/

〈 〉